Clinical implications of intratumoral heterogeneity of HER2 gene amplification in locally advanced HER2-positive breast cancer patients.
Department of Medical Oncology, Hacettepe University Cancer Institute, 06100 Ankara, Turkey.
Bekir
B
Hacioglu
Department of Medical Oncology, Hacettepe University Cancer Institute, 06100 Ankara, Turkey.
Serkan
S
Akin
Department of Radiology, Hacettepe University School of Medicine, Ankara, Turkey.
Ali R
AR
Sever
Department of Medical Oncology, Hacettepe University Cancer Institute, 06100 Ankara, Turkey.
Kadri
K
Altundag
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D005260:Female; D005784:Gene Amplification; D018740:Genetic Heterogeneity; D006801:Humans; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases
HER2-positive; adjuvant; breast cancer; chemotherapy; complete remission; intratumoral heterogeneity; locally advanced; neoadjuvant; receptors; trastuzumab